Hexima Limited (ASX:HXL)

Request removal

Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (formally HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.

URLs

website: http://www.hexima.com.au
twitter: https://twitter.com/HeximaLimited
linkedin: http://www.linkedin.com/company/hexima-limited

Get valid emails for people working at Hexima Limited (ASX:HXL) and 200M other companies

20 free emails each month. No credit card required.

500M

Business Profiles

20M

Company Profiles

200M

Email addresses

98%+

Email Delivery

Hexima Limited (ASX:HXL)'s headquarter address

Line 1: la trobe institute for molecular science, level 4, lims 2, la trobe university, melbourne, victoria, australia

Line 2: Science Dr

Hexima Limited (ASX:HXL)'s industries

biotechnology

Hexima Limited (ASX:HXL)'s technology

Bootstrap Framework Citrix NetScaler Google Analytics Google Font API Google Maps Google Tag Manager Mobile Friendly New Relic Nginx Outlook WordPress.org